|drug1589||Lopinavir / ritonavir tablets combined with Xiyanping injection Wiki||1.00|
|drug1606||Lopinavir/ritonavir treatment Wiki||1.00|
|D045169||Severe Acute Respiratory Syndrome NIH||0.05|
|D018352||Coronavirus Infections NIH||0.04|
There is one clinical trial.
This Phase I is designed to evaluate the safety, tolerability and pharmacokinetics of multiple ascending doses of M201-A administered by multiple continuous intravenous injection in Healthy Japanese subjects.
Description: Number of participants with adverse events, serious adverse events, physical examinations, vital sign measurements, 12-lead ECGs, Holter ECG, clinical laboratory safety tests (including hematology, chemistry, and urinalysis), recording of concomitant medications and procedures.Measure: Number of participants with adverse events as a measure of safety and tolerability Time: Throughout the study duration up to day 11